Levodopa News and Research

RSS

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Abbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).

18 Apr 2012

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

A levodopa-carbidopa intestinal gel (LCIG) works better than standard oral levodopa-carbidopa in reducing "off" time in patients with advanced Parkinson's disease.

18 Apr 2012

OPKO Health, Scripps Research partner to commercialize Parkinson's disease compound, SR 3306

The Scripps Research Institute and OPKO Health, Inc. today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

TSRI, OPKO Health to develop and commercialize SR 3306 for Parkinson's

OPKO Health, Inc. and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

Impax announces FDA acceptance of NDA filing for IPX066

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for IPX066 for the treatment of idiopathic Parkinson's disease (PD) submitted to the Agency on December 21, 2011.

23 Feb 2012

Study to quantify benefits of aerobic exercise in managing Parkinson's symptoms

Daniel Corcos has studied Parkinson's disease for more than 20 years. For most of the past 10, he has focused on the effects of exercise. "It became obvious several years ago that exercise really was good for people with Parkinson's disease," said Corcos, who is professor of kinesiology and nutrition at the University of Illinois at Chicago. "Not only is it good for the heart, the brain, and muscles in the same way it is for healthy people, it also modifies signs and symptoms of Parkinson's disease."

17 Feb 2012

DBS safe and effective for patients with advanced Parkinson's

Researchers from the University of Florida and 14 additional medical centers reported results today in the online version of The Lancet Neurology journal indicating that deep brain stimulation - also known as DBS - is effective at improving motor symptoms and quality of life in patients with advanced Parkinson's disease.

12 Jan 2012

Positive topline results from Civitas' CVT-301 Phase 1 trial on PD

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.

7 Jan 2012

Impax submits IPX066 NDA to FDA for treatment of Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.

22 Dec 2011

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

XenoPort, Inc. announced today preliminary top-line results of a Phase 2, randomized, crossover clinical trial that compared optimized treatment with either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated with carbidopa (279/CD) in advanced Parkinson's disease patients with motor fluctuations.

5 Dec 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011

Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.

28 Sep 2011

Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., has been awarded funding of up to $400,000 by The Michael J. Fox Foundation for ongoing clinical research of the Company's investigational carbidopa-levodopa extended release (CD-LD ER) product IPX066, which is intended to treat the motor symptoms of Parkinson's disease (PD).

14 Jul 2011

Lund University professor receives Robert A. Pritzker Prize for Parkinson's research

Anders Björklund from Lund University in Sweden has been awarded the Robert A. Pritzker Prize for his many years of leadership in research on Parkinson's disease. The prize has long been an institution in American architecture and this year, for the first time, it is also being awarded to recognise cutting-edge medical research.

16 Jun 2011

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

9 Jun 2011

Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 ADVANCE-PD and APEX-PD Phase III clinical study data will be presented in Poster Sessions at the 15th International Congress of Parkinson's Disease and Movement Disorders Conference in Toronto, Canada, held from June 5 to June 9.

4 Jun 2011

Lilly and Medtronic’s joint venture in Parkinson’s disease therapy

Lilly has already developed a protein called GDNF (glial cell line derived neurotrophic factor) known to preserve the function of neurons and Medtronic will provide a system that carries the medicine to a key area of the brain.

From Medtronic 26 Apr 2011

APEX-PD Phase III clinical study data to be presented at American Academy of Neurology Conference

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 APEX-PD Phase III clinical study data will be presented in a Late Breaker Session at the 63rd annual meeting of the American Academy of Neurology Conference in Honolulu, Hawaii, held from April 9 to April 16.

1 Apr 2011

China BCT fourth quarter revenue increases 82.3% to $66.8 million

China BCT Pharmacy Group, Inc.,, a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced results for the fourth quarter and full year ended December 31, 2010.

31 Mar 2011

Gene therapy holds promise for Parkinson's treatment

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.

17 Mar 2011